Biblio
Export 1991 results:
Author Title [ Type
Filters: First Letter Of Last Name is B [Clear All Filters]
“Brain Aging and Late-Onset Alzheimer's Disease: A Matter of Increased Amyloid or Reduced Energy?”, J Alzheimers Dis, vol. 64, no. s1, pp. S397-S404, 2018.
, “Brain Aging and Late-Onset Alzheimer's Disease: A Matter of Increased Amyloid or Reduced Energy?”, J Alzheimers Dis, vol. 64, no. s1, pp. S397-S404, 2018.
, “Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.”, J Alzheimers Dis, vol. 66, no. 1, pp. 229-237, 2018.
, “Brain Biomarkers in Familial Alzheimer's Disease Mouse Models.”, J Alzheimers Dis, vol. 60, no. 3, pp. 949-958, 2017.
, “Brain Metabolism Correlates of the Free and Cued Selective Reminding Test in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 1, pp. 27-31, 2016.
, “Brain Volume Predicts Behavioral and Psychological Symptoms in Alzheimer's Disease.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1343-1353, 2020.
, “Brain Volume Predicts Behavioral and Psychological Symptoms in Alzheimer's Disease.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1343-1353, 2020.
, “Brain Volume Predicts Behavioral and Psychological Symptoms in Alzheimer's Disease.”, J Alzheimers Dis, vol. 73, no. 4, pp. 1343-1353, 2020.
, “Burden of Insomnia and Sleep Disturbances and the Impact of Sleep Treatments in Patients with Probable or Possible Alzheimer's Disease: A Structured Literature Review.”, J Alzheimers Dis, vol. 86, no. 1, pp. 83-109, 2022.
, “Can 11C-PiB-PET Relative Delivery R1 or 11C-PiB-PET Perfusion Replace 18F-FDG-PET in the Assessment of Brain Neurodegeneration?”, J Alzheimers Dis, vol. 65, no. 1, pp. 89-97, 2018.
, “Can Diet Supplements of Macular Pigment of Lutein, Zeaxanthin, and Meso-zeaxanthin Affect Cognition?”, J Alzheimers Dis, vol. 87, no. 3, pp. 1079-1087, 2022.
, “Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old.”, J Alzheimers Dis, vol. 90, no. 1, pp. 405-417, 2022.
, “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.
, “Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 64, no. 2, pp. 379-392, 2018.
, “Cardiorespiratory Fitness Attenuates the Deleterious Effects of Sleep Apnea on Cerebral Structure and Perfusion in the Wisconsin Sleep Cohort Study.”, J Alzheimers Dis, vol. 95, no. 2, pp. 427-435, 2023.
, “Cardiorespiratory Fitness Attenuates the Deleterious Effects of Sleep Apnea on Cerebral Structure and Perfusion in the Wisconsin Sleep Cohort Study.”, J Alzheimers Dis, vol. 95, no. 2, pp. 427-435, 2023.
, “Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1045-1052, 2022.
, “Caregiving and Caregiver Burden in Dementia Home Care: Results from the Prospective Dementia Registry (PRODEM) of the Austrian Alzheimer Society.”, J Alzheimers Dis, vol. 63, no. 1, pp. 103-114, 2018.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
, “CD44 Splice Variants as Potential Players in Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1137-1149, 2017.
, “Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.
, “Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.
, “Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.
, “Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1113-1121, 2018.
,